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Chapter 10
 Valorizati on addendum
Among the health issues that the youth of today is facing in developed countries, 
obesity and allergic disease are two of the most serious ones, with life-long conse-
quences. Indeed, the European Commission classifi es childhood obesity and al-
lergy as two chronic conditions of major public health importance.1 It is estimated 
that around 50 million girls and 74 million boys worldwide are currently obese, 
while 213 million children are in the range of overweight, but below the obesity 
threshold.2 Moreover, according to the most recent estimates, approximately 1 in 
every 10 children aged 14 years or less worldwide suff er from asthma.3 Hence, 
there is an urgent need to identify modifi able determinants that can be targeted 
for preventive strategies. Such strategies are likely to bring substantial benefi ts 
over the whole lifespan (Figure 10.1).
Figure 10.1. Stakeholder statements on the importance of noncommunicable disease preven-
ti on in early life.
Our work strengthens the evidence that nutrition during pregnancy, which is 
a highly modifi able lifestyle factor, can infl uence child obesity and asthma. We 
focused on prenatal polyunsaturated fatty acid concentrations and fi sh intake, 
for which previous research has yielded largely inconsistent results (see Chapter 
1), thus limiting health risk assessments. Our work has relevance for a number of 
policy documents including the European food Action Plan 2015-20204 and the 
European policy framework Health 20205, both of which underscore the impor-
tance of providing healthy food and nutrition across the lifecourse as a means for 
promoting population health. Moreover, it addresses the recent European Coun-
cil’s conclusions towards halting childhood obesity, which highlight the need for 
further research to understand the drivers of childhood overweight and obesity to 
explore approaches to a healthy diet across the life course.6
Potential end-users of our research can be identifi ed at various ecological levels: 
individual level (e.g. parents, future parents), community level (e.g. physicians, 
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local communities), national level (food industry, think-tanks, public health insti-
tutes), European and international level (e.g. patient organizations, food industry, 
EFSA, WHO, Schools for Public Health Europe). 
Claims about the numerous potential health benefits of omega-3 fatty acids 
have contributed substantially to the increase of the global omega-3 supplement 
market, with its value being estimated at around USD 33.04 billion in 2016.7 
Our findings on n-3 long-chain PUFA supplementation in the perinatal period 
(Chapter 2) and those on cord blood PUFA biomarker levels (Chapters 3, 4, and 
5), in addition to findings of other studies, may have implications for productive 
and commercial activities used by the food industry.
Nutrient-based studies using biomarker levels may provide more insight on mech-
anistic pathways through which food products containing numerous nutrients 
can affect health and development. In our studies on cord blood PUFA biomarker 
levels, we did not have information on prenatal dietary intake so as to unravel 
the amount of dietary PUFAs or PUFA-containing foods (see Chapter 1) needed 
in order to achieve a change in biomarker levels.  Together with prior research 
findings, our results could jointly be used for formulating dietary recommenda-
tions for pregnant woman. Currently, a number of health or patient organization 
produce such recommendations, including but not limited to the World Health 
Organization (WHO), Health Council of the Netherlands,8 Greek Institute of 
Preventive Medicine, Environmental and Occupational Health (Prolepsis),9 U.S. 
Department of Health and Human Services and U.S. Department of Agricul-
ture,10 and Public Health England.11
In 2015, the European Food Safety Authority (EFSA) in its statement on the 
benefits of fish/seafood consumption compared to the risks of methylmercury in 
fish/seafood concluded that pregnant women should consume up to 3-4 servings 
of fish per week.12 In January 2017, the US Food and Drug Administration (FDA) 
and Environmental Protection Agency (EPA) issued their final updated advice 
on fish consumption for women of childbearing age,  encouraging women who 
are pregnant, breastfeeding, or likely to become pregnant to consume more fish, 
but no more than 3 servings/week.13 Notably, fish advisories have focused on the 
potential neurocognitive harms associated with exposure to methyl-mercury but 
have not considered other childhood outcomes, including obesity and asthma, 
areas where evidence is generally quite limited. Hence, our international studies 
on fish intake during pregnancy aimed to address this knowledge gap (Chapters 
7 and 8). Our findings that fish intake of more than 3 times per week during 
pregnancy is associated with an increased risk of rapid infant growth and child-
hood overweight/obesity are in line with the limit proposed by FDA and EPA, but 
not with the EFSA conclusion.  
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We used a wide range of tools to disseminate knowledge generated from this work 
(Figure 10.2). We published our work in leading international fully peer-reviewed 
journals and one book chapter to increase awareness and communicate our study 
fi ndings within the scientifi c community. Our study results were also presented 
at the Dutch Epidemiological Society (WEON) conferences (2014, 2015, 2016), 
with an audience consisting mostly of researchers and clinicians. Moreover, we 
showed our results to Th e Obesity Society (TOS) Obesity Week (2015), the Inter-
national Society for the Study of Fatty Acids and Lipids (ISSFAL) congress (2016) 
and the Euro Fed Lipid Congress (2016), in which food industry had also an active 
participation. Additionally, we developed the MEFAB birth cohort website (www.
mefab.org), with links to specifi c pages for scientifi c and non-scientifi c audiences. 
An example of the latter is a page (www.mefab.org/wist-je-dat) that explains in 
lay language the health issues surrounding early-life nutrition and our most recent 
research fi ndings. Furthermore, we developed a documentary about the paradigm 
of “developmental origins of health and disease” and the contribution of the ME-
FAB cohort in this research fi eld (https://youtu.be/Bc6MEAULY08). Given that 
social media constitute an eff ective way of reaching the lives of many people and 
sharing knowledge nowadays, we created social media accounts (Facebook, twit-
ter) for the MEFAB cohort, where we disseminated knowledge generated from 
this work in a simple and direct way. Furthermore, our fi ndings on fi sh intake 
during pregnancy and childhood growth and obesity received international press 
coverage, being mentioned in prominent news media including but not limited 
to CNN (http://cnn.it/2hxe43l), Reuters (http://reut.rs/2jAPrqv), and TIME 
(http://ti.me/1PMES7S).
Figure 10.2. Disseminati on channels used for our work and potenti al end-users.
To conclude, our work focused on childhood obesity and asthma, which consti-
tute public health priorities, and therefore, has major potential for translational 
utilization. It examined the infl uence of two highly modifi able lifestyle factors 
(PUFA levels and fi sh intake) during the prenatal period, which is critical period 
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of developmental plasticity. Evidence from this work are positioned to inform (fu-
ture) parents for dietary advice, and better policy- and decision-making for public 
health interventions. Interventions specifically targeting this early-life period are 
considered to have a large and long-lasting impact across the life course, and thus, 
give substantial long-term social and economical returns on investment.
